RenovoRx, Inc. RNXT
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +58.33%
- 1 year
- +31.68%
- Open
- 1.49
- Prev close
- 1.49
- Mkt cap
- 60.02M
- Vol
- 376.39K
- Avg vol
- 810.88K
- EPS
- -0.31
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.34
- High
- 1.50
- Forward P/E
- -3.10
- Beta
- 0.99
- Short ratio
- 3.43
- Inst. own
- 8.18%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 1.14
- 200-d avg
- 1.18
- 1y target
- 5.50
5D chart
Signals (58)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 29, 3:55 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:55 PM | 2 days ago |
| RSI: Oversold | Oct 29, 3:05 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 2:35 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:55 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:50 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 12:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:25 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:00 PM | 4 days ago |
| RSI: Overbought | Oct 27, 1:55 PM | 4 days ago |
| RSI: Overbought | Oct 27, 12:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:50 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 10:00 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 26, 3:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 1:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 12:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 11:55 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 11:30 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:55 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
| MACD: Sell Signal | Oct 26, 10:30 AM | 6 days ago |
| MACD: Buy Signal | Oct 26, 10:15 AM | 6 days ago |
| MACD: Sell Signal | Oct 26, 10:05 AM | 6 days ago |
| RSI: Overbought | Oct 23, 3:55 PM | 1 week ago |
| SMA: Bullish | Oct 23, 2:50 PM | 1 week ago |
| SMA: Bullish | Oct 23, 2:50 PM | 1 week ago |
| SMA: Bearish | Oct 23, 2:40 PM | 1 week ago |
| SMA: Bearish | Oct 23, 2:40 PM | 1 week ago |
| MACD: Buy Signal | Oct 23, 2:25 PM | 1 week ago |
| SMA: Bullish | Oct 23, 2:20 PM | 1 week ago |
| SMA: Bearish | Oct 23, 10:40 AM | 1 week ago |
News
4 days ago globenewswire.com
RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
MOUNTAIN VIEW, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and…
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 7.8% to $1.52 during Friday's after-market session. The market value of their outstanding shares is at $3.3 million. 20/20 Biolabs…
-
3 weeks ago benzinga.com
RenovoRx Enrolls First Participant In PRISM-TAMP, “PDAC Regression And Intraoperative Surgical Margin With Neoadjuvant TAMP Study
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared
-
1 month ago benzinga.com
RenovoRx Announces Publication Of Peer-Reviewed Case Series In Case Reports In Oncology From Researchers At Hackensack Meridian Health’s Jersey Shore University Medical Center
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared
-
2 months ago benzinga.com
Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14.5
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $14 to $14.5.
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Picard Medical (AMEX:PMI) shares moved upwards by 82.7% to $9.38 during Tuesday's regular session. The market value of their outstanding shares is at $10.5 million. As per the news, the Q2…
-
2 months ago benzinga.com
RenovoRx Announces Publication Of Sub-Study Data From Its Ongoing Phase III TIGeR-PaC Clinical Trial In The Journal Cancer Chemotherapy And Pharmacology; Data Show Trans-Arterial Micro-Perfusion-Mediated Delivery Concentrated Chemotherapy At The Tumor Site, Extracting ~51% Of Drug Locally Before It Entered The Bloodstream, Meaningfully Lowering Systemic Exposure
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared
-
2 months ago benzinga.com
RenovoRx Says USPTO Issues Notice Of Allowance For Patent Application Titled Methods And Apparatuses For Delivery Of Therapeutic Materials For The Treatment Of Cancer
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market session. The market value of their outstanding shares is at $2.4 million. Omeros (NASDAQ:OMER) stock…
-
2 months ago benzinga.com
RenovoRx Raises FY2026 Sales Guidance from $3.000M-$4.000M to $3.750M-$4.250M vs $3.203M Est
RenovoRx (NASDAQ:RNXT) raises FY2026 sales outlook from $3.000 million-$4.000 million to $3.750 million-$4.250 million vs $3.203 million estimate.
-
2 months ago benzinga.com
RenovoRx Q2 Adj. EPS $(0.05) Beats $(0.07) Estimate, Sales $909.000K Beat $716.500K Estimate
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 37.5 percent increase over losses of $(0.08) per…
2 months ago benzinga.com
EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027
RenovoRx finishes Phase 3 TIGeR-PaC trial enrollment for locally advanced pancreatic cancer, expecting topline data in H2 2027.
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers P3 Health Partners (NASDAQ:PIII) shares increased by 24.1% to $15.92 during Monday's after-market session. The market value of their outstanding shares is at $38.5 million. As per the press…
5 months ago benzinga.com
Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know
Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price targets raised/cut, ratings maintained/changed.
-
5 months ago benzinga.com
Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $13.5 to $14.
-
5 months ago benzinga.com
RenovoRx Announces FDA Orphan Drug Designation Of Oxaliplatin For The Treatment Of Pancreatic Cancer
The designation was issued by the FDA's Office of Orphan Products Development pursuant to Section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb). Oxaliplatin is an approved and…
-
5 months ago benzinga.com
RenovoRx Announces Online Publication Of Abstract From Pharmacokinetic And Pharmacodynamic Sub-Study Of Ongoing Phase III TIGeR-PaC Clinical Trial In Connection With 2026 ASCO Annual Meeting
Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic…
-
5 months ago benzinga.com
RenovoRx Reports Q1 2026 Results: Full Earnings Call Transcript
RenovoRx Reports Q1 2026 Results: Full Earnings Call Transcript
-
5 months ago benzinga.com
RenovoRx Affirms FY2026 Sales Guidance of $3.000M-$4.000M vs $3.244M Est.
RenovoRx (NASDAQ:RNXT) affirms FY2026 sales outlook from $3.000 million-$4.000 million to $3.000 million-$4.000 million vs $3.244 million estimate.
-
5 months ago benzinga.com
RenovoRx Q1 Adj. EPS $(0.08), Inline, Sales $563.000K Beat $463.250K Estimate.
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 14.29 percent decrease over losses of $(0.07) per share from the same period…
-
6 months ago benzinga.com
Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $13.5
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $13 to $13.5.
-
6 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on RenovoRx, Maintains $3 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates RenovoRx (NASDAQ:RNXT) with a Buy and maintains $3 price target.
-
6 months ago benzinga.com
RenovoRx Secures Notice Of Allowance From Japan Patent Office For Application Titled "Method and Apparatus for Delivering an Agent Through the Vasa Vasorum"
The allowed claims of the patent protect the RenovoCath dual-occlusion catheter-based system equipped with integrated imaging and pressure-sensing technology that is designed to enable targeted…
-
7 months ago benzinga.com
RenovoRx Q4 EPS $(0.08), Inline, Sales $238.000K Miss $419.750K Estimate
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 33.33 percent increase over losses of $(0.12) per share from the same period…
-
7 months ago benzinga.com
Earnings Scheduled For March 30, 2026
Earnings Scheduled For March 30, 2026
-
7 months ago benzinga.com
RenovoRx Announces $10M At-The-Market Private Placement For Oversubscribed Common Stock And Milestone Warrant Private Placement
The proceeds from this financing are expected to allow RenovoRx to capitalize on and accelerate its commercialization efforts for RenovoCath® in 2026 as the Company seeks to increase revenue, reduce…
-
8 months ago benzinga.com
RenovoRx Announces 12 U.S. Centers Using Its RenovoCath Device
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared…
8 months ago benzinga.com
Micron To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Tuesday
Micron To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Tuesday
-
8 months ago benzinga.com
Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $13
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $12.5 to $13.
-
8 months ago benzinga.com
RenovoRx Creates RenovoCath Medical Advisory Board For Its Clinical, Strategic Initiatives
RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared…
-
8 months ago benzinga.com
RenovoRx Appoints Mark Voll CFO, Effective Feb. 1
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared…
-
9 months ago benzinga.com
RenovoRx To Present New Clinical Data At 2026 Society Of Interventional Oncology Annual Scientific Meeting On Feb. 6
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared…
-
9 months ago benzinga.com
RenovoRx's Abstract Submission Accepted
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared…
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
9 months ago benzinga.com
Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
-
9 months ago benzinga.com
RenovoRx To Present New Clinical Data Abstract From PK And Pharmacodynamic Sub‑Study Of Ongoing Phase III TIGeR‑PaC Clinical Trial At 2026 ASCO GI
New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx's TAMP Therapy Platform as a Targeted Drug-Delivery ApproachData Shows a…
9 months ago benzinga.com
Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
11 months ago benzinga.com
RenovoRx Q3 EPS $(0.08), Inline, Sales $266.000K Miss $405.333K Estimate
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 20 percent increase over losses of $(0.10) per share from the same period…
-
11 months ago benzinga.com
Earnings Scheduled For November 13, 2025
Earnings Scheduled For November 13, 2025
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
1 year ago benzinga.com
RenovoRx Completes First Registry-Eligible Patient Procedure In PanTheR Post-Marketing Registry Study At University Of Vermont Cancer Center
First Registry-Eligible Patient Procedure Commenced at the University of Vermont Cancer CenterBaptist Health Miami Cancer Institute and University of Pittsburgh Medical Center Join the University of…
1 year ago benzinga.com
Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge
Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Edge Stock Rankings.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
RenovoRx Announces The Independent Data Monitoring Committee For Its Ongoing Phase III TIGeR-PaC Trial Has Recommended To Continue The Study
"At the same time, we are very excited to report that the independent Data Monitoring Committee (DMC) for our ongoing Phase III TIGeR-PaC trial recently completed their review of our second…
-
1 year ago benzinga.com
RenovoRx Q2 EPS $(0.08) Beats $(0.09) Estimate, Sales $422.00K Beat $329.67K Estimate
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 8.05 percent. This is a 20 percent increase over losses of $(0.10) per…
-
1 year ago benzinga.com
Earnings Scheduled For August 14, 2025
Earnings Scheduled For August 14, 2025
-
1 year ago benzinga.com
RenovoRx Expands RenovoCath Commercial Reach To 13 Cancer Centers
RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCathFour active cancer center customers are…